Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.240 +0.070 (+5.98%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	94,708
Open	1.180
Bid (Size)	1.210 (100)
Ask (Size)	1.230 (1,400)
Prev. Close	1.170
Today's Range	1.150 - 1.280
52wk Range	0.0661 - 3.250
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

March 30, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

March 27, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Performance

YTD	-37.7%	-37.7%
1 Month	+21.6%	+21.6%
3 Month	-50.2%	-50.2%
6 Month	+22.8%	+22.8%
1 Year	+27.8%	+27.8%

More News

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

March 19, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

March 17, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

March 13, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

March 11, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

March 10, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

March 04, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

February 09, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

February 06, 2026

From Polyrizon Ltd.

Via GlobeNewswire

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

February 06, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

February 03, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

January 20, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

January 14, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

December 31, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

December 24, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

December 16, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

December 12, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

December 12, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2025-12-11: top gainers and losers in today's session. ↗

December 11, 2025

Via Chartmill

Top stock movements in today's session. ↗

December 11, 2025

Via Chartmill

The market is filled with gapping stocks in Thursday's session. ↗

December 11, 2025

Via Chartmill

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

December 11, 2025

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

December 10, 2025

Via Chartmill

Clearmind Medicine Announces 1-for-40 Reverse Share Split

December 10, 2025

From Clearmind Medicine Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?

Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.

What exchange does Clearmind Medicine Inc. - Common Shares trade on?

Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?

The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market

What is the current price of Clearmind Medicine Inc. - Common Shares?

The current price of Clearmind Medicine Inc. - Common Shares is 1.240

When was Clearmind Medicine Inc. - Common Shares last traded?

The last trade of Clearmind Medicine Inc. - Common Shares was at 04/07/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.